Examining the link between IGF-1 levels and body mass index in acne patients
Relation Between Serum Insulin Like Growth Factor 1 and Body Mass Index in Acne Vulgaris
This study is trying to see if there’s a connection between IGF-1 levels and body weight in people aged 15 to 45 who have acne.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 15 Years to 45 Years |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Cairo, Qalubya) |
| Trial ID | NCT05301569 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the relationship between serum levels of Insulin-like Growth Factor 1 (IGF-1) and body mass index (BMI) in patients suffering from acne vulgaris. Participants aged 15 to 45 will be recruited from dermatology and andrology outpatient clinics at Assuit University Hospital in Egypt. After a thorough examination by dermatologists and obtaining informed consent, data will be collected to analyze the correlation between IGF-1 levels and BMI in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 15 to 45 who are experiencing acne vulgaris.
Not a fit: Patients with insulin resistance, diabetes, polycystic ovarian syndrome, or those on certain medications affecting IGF-1 levels will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of IGF-1 in acne development, potentially leading to better-targeted treatments.
How similar studies have performed: While the specific relationship between IGF-1 and acne vulgaris has not been extensively studied, similar investigations into hormonal influences on acne have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged from 15 to 45 years old suffering from acne vulgaris. 2. Both sexes. Exclusion Criteria: 1. Insulin resistance and diabetic patients 2. Females with polycystic ovarian syndrome 3. Treatment with drugs that can influence IGF-1level such as corticosteroid, insulin, hypoglycemic agents, and isotretinoin within one year before the date of study. 4. Other causes of acne or acneform eruption as steroid-induced
Where this trial is running
Cairo, Qalubya
- Rania Sallam — Cairo, Qalubya, Egypt (Recruiting)
Study contacts
- Study coordinator: Rania Sallam
- Email: Raniamohamed0887@gmail.com
- Phone: 113567939
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.